ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,268.20
0.33%
S&P ASX All Technology
3,778.40
-0.54%
Brent Oil
73.18
1.19%
US Dollar vs AUD
1.5952
0.66%
Bitcoin
85,572.07
1.78%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Stoke Therapeutics Inc (STOK) Share Price

Stoke Therapeutics Inc

Stoke Therapeutics Inc (STOK)

NASDAQ
8.27
0.02
(0.24%)
Closed 27 February 8:00AM
Delayed by 15 minutes
8.27
0.00
( 0.00% )
Pre Market: 12:48AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
8.27
Bid
8.00
Offer
8.37
Volume
25
0.00 Day's Range 0.00
5.60 52 Week Range 17.58
Market Cap
438.037M
Previous Close
8.27
Open
-
Last Trade
4
@
8.37
Last Trade Time
00:10:44
Financial Volume
-
VWAP
-
Average Volume (3m)
816,623
Shares Outstanding
52,966,977
Dividend Yield
-
PE Ratio
-4.18
Earnings Per Share (EPS)
-1.98
Revenue
8.78M
Net Profit
-104.7M

About Stoke Therapeutics Inc

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.stoketherapeutics.com
Headquarters
Dover, Delaware, USA
Founded
-
Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STOK. The last closing price for Stoke Therapeutics was US$8.27. Over the last year, Stoke Therapeutics shares have traded in a share price range of US$ 5.60 to US$ 17.58.

Stoke Therapeutics currently has 52,966,977 shares in issue. The market capitalisation of Stoke Therapeutics is US$438.04 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -4.18.

Ask ADVFN Intelligence (AI)

STOK Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
19 February 2025
STOK (0.24%)

Form 8-K - Current report
Edgar (US Regulatory)
07 January 2025
STOK (0.24%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
28 December 2024
STOK (0.24%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.03-11.07526881729.39.338.139589658.48615111CS
4-2.39-22.420262664210.6612.988.1387153710.32361549CS
12-4.26-33.998403830812.5314.3858.1381662310.57927026CS
26-5.86-41.472045293714.1316.158.1367396111.78375374CS
521.5823.61733931246.6917.585.683916312.31897198CS
156-11.15-57.415036045319.4226.63.3547052211.57604175CS
260-16.69-66.866987179524.9671.583.3535069315.53318914CS

STOK - Frequently Asked Questions (FAQ)

What is the current Stoke Therapeutics share price?
The current share price of Stoke Therapeutics is US$ 8.27
How many Stoke Therapeutics shares are in issue?
Stoke Therapeutics has 52,966,977 shares in issue
What is the market cap of Stoke Therapeutics?
The market capitalisation of Stoke Therapeutics is USD 438.04M
What is the 1 year trading range for Stoke Therapeutics share price?
Stoke Therapeutics has traded in the range of US$ 5.60 to US$ 17.58 during the past year
What is the PE ratio of Stoke Therapeutics?
The price to earnings ratio of Stoke Therapeutics is -4.18
What is the cash to sales ratio of Stoke Therapeutics?
The cash to sales ratio of Stoke Therapeutics is 49.88
What is the reporting currency for Stoke Therapeutics?
Stoke Therapeutics reports financial results in USD
What is the latest annual turnover for Stoke Therapeutics?
The latest annual turnover of Stoke Therapeutics is USD 8.78M
What is the latest annual profit for Stoke Therapeutics?
The latest annual profit of Stoke Therapeutics is USD -104.7M
What is the registered address of Stoke Therapeutics?
The registered address for Stoke Therapeutics is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Stoke Therapeutics website address?
The website address for Stoke Therapeutics is www.stoketherapeutics.com
Which industry sector does Stoke Therapeutics operate in?
Stoke Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TRIThomson Reuters Corporation
US$ 178.40
(790.66%)
2.4k
ULYUrgent ly Inc
US$ 0.914
(117.62%)
45.73M
XNETXunlei Ltd
US$ 5.04
(73.79%)
21.09M
ANNAAleAnna Inc
US$ 11.31
(59.97%)
11
NIXXNixxy Inc
US$ 2.25
(42.41%)
30.6M
SUNESUNation Energy Inc
US$ 0.4711
(-59.03%)
525.26k
TOIIWOncology Institute Inc
US$ 0.0186
(-54.52%)
2
DMRCDigimarc Corporation
US$ 18.26
(-32.47%)
47.79k
UVSPUnivest Financial Corporation
US$ 21.17
(-29.34%)
6
LICNLichen China Limited
US$ 0.0495
(-28.47%)
15.82M
ULYUrgent ly Inc
US$ 0.9165
(118.21%)
45.73M
NIXXNixxy Inc
US$ 2.25
(42.41%)
30.6M
QNRXQuoin Pharmaceuticals Ltd
US$ 0.3721
(20.89%)
30.46M
TRNRInteractive Strength Inc
US$ 1.7197
(37.58%)
29.35M
XNETXunlei Ltd
US$ 5.09
(75.52%)
21.07M

STOK Discussion

View Posts
PonkenPlonken PonkenPlonken 3 months ago
I am so STOKED about this company. They were doing this before they all figured out you need RNA science for gene therapy.
See SRPT ARWR deal! another AAV based gene tx seeking RNAI
👍️0
Monksdream Monksdream 6 months ago
FOLD under $15
👍️0
Zardiw Zardiw 11 months ago
$STOK Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
TimeFades TimeFades 11 months ago
Choppy day shoulda just stuck with my morning short
👍️0
TimeFades TimeFades 11 months ago
Got bullish again and covered
👍️0
TimeFades TimeFades 11 months ago
Short from 12s
👍️0
Invest-in-America Invest-in-America 11 months ago
STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
👍️0

Your Recent History

NASDAQ
STOK
Stoke Therapeutics
BIT
P1T6C3
BNP Paribas Issuance
BIT
XLFS
Invesco Financials S&P U...
BIT
NTSX
ETF
BIT
UC8HXN
Unicredit Bank
AQSE
HCM.GB
HUTCHMED China
BIT
Q00550
Leonteq Securities
BIT
Q00318
Leonteq Securities
BIT
F39191
Vontobel Financial Produ...
BIT
EMV
Exchange Traded
BIT
I04622
Banca IMI
BIT
FNL
Finlogic
BIT
I07825
Intesa Sanpaolo
BIT
F20455
Vontobel Financial Produ...
BIT
ADA113
Amagis Dynamic Alloc Tot...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads